Rentabilitas dodolan miturut bathi resik: Adlai Nortye Ltd. (ANL)

adlainortye.com - logo grafis emiten ANL

International leadership experience in developing oncology drugs has laid the foundation for Adlai Nortye Ltd. (ANL) business expansion. The net profitability trend visualizes this growth, where -124.80 reflects the latest metric value. The development of innovative buparlisib against resistant tumors enhances the company's potential, while the expansion of its center network in Asia and the US, coupled with full patient retention, ensures stability ahead of FDA approval.

Rentabilitas dodolan resik Adlai Nortye (ANL): kanggo periode 21.02.2024 - 20.11.2026

Adlai Nortye Ltd (ANL) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Pambiji fundamental perusahaan:Adlai Nortye Ltd, ANL
Produk asil prodhuksi Adlai Nortye

Geopolitical tensions and sanctions between China and the US are hindering the global clinical trials of Adlai Nortye Ltd. (ANL). These logistical disruptions directly impact operating expenses, distorting bottom-line profits. This metric measures the share of net income in total revenue, determining the real efficiency of the business. This metric allows for an assessment of the issuer's financial stability and helps avoid overpaying for the asset. An analysis of the net profit margin trend confirms the company's ability to generate profit.

Analisis perusahaan pesaing

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|Veru Inc - Margin dodolan resik|Margin dodolan perusahaan Tempest Therapeutics TPST|XLO: Margin dodolan resik|Enochian BioSciences (RENB) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik MURA|Kairos Pharma Ltd - Margin bathi resik|Margin dodolan resik OKUR|CytoMed Therapeutics Limited (GDTC) - Tingkat bathi miturut bathi resik|Margin dodolan resik CRIS (Curis, Inc.)|APLM: Rentabilitas dodolan resik|Tharimmune Corporation - Margin dodolan resik|ADVB: Margin resik|GNPX: Margin dodolan resik|CLDI (Calidi Biotherapeutics Inc.) - Margin resik|Margin resik Sunshine Biopharma, Inc.|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)